Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.467527625
Author: Trendlyne DVM scores

Mid-range Performer

about

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

123.20 1.44 (1.18%)

Near 52W High of $128.70

1.9M

XNAS Volume

XNAS 14 Jan, 2026 1:56 PM (EST)

Medium Financial Strength

44.4 / 100

Affordable Valuation

58.8 / 100

Technically Neutral

49.7 / 100

Mid-range Performer These stocks have affordable valuations, but mid range financials and momentum View Similar Embed DVM

134

1Yr Price target upside is 9%

26 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

Near 52W High of $128.70

SWOT Analysis

Gilead Sciences Live Price Chart